Background: Hepatitis C virus (HCV) infection represents a major health burden According to the world health organization (WHO) there are more than 170 million people infected worldwide and 3-4 million new infections are estimated per year. Recent studies have demonstrated the role of interleukin B 28(IL B 28) polymorphism in predicting the treatment induced and spontaneous clearance from hepatitis C virus (HCV) infection and genome-wide association studies have shown that single nucleotide polymorphism (SNPs) near interleukin 28B gene are good predictors of response to treatment. The present study aimed to isolate and identify IL 28 B gene rs8099917 polymorphism from HCV infected individuals DNA.
Methods: This cross-sectional study was performed on 50 blood samples from patients with chronic HCV infection as detected by ELISA kit (RIBA-11 and c-200/c-22 ELISA Company and country). DNA was extracted from the samples and the frequency of the polymorphism was analyzed by using PCR-RFLP method.
Results: The analysis of the data for G/T polymorphism showed that GT heterozygous was found in 14(28%) patients (10 males, 4 females), and TT homozygote was detected in 36(72%) patients (26 males, 10 females) and no GG homozygous genotype was detected.
Conclusion: In this study investigation of rs8099917 (T/G) Polymorphism in interleukin 28B gene (IL28B) in 50 HCV positive patients from Khartoum State indicated that the TT genotype was the dominant genotype detected.
Published Date: 2019-11-13; Received Date: 2019-10-22